HTRA1与SLC7A11相互作用,通过抑制铁化,调节结直肠癌的化学敏感性
Weiwei Liu1,2, Chaoqun Liu2,3, Jun Xiao2,3
1Department of Pathology, Shunde Hospital, Southern Medical University, Foshan, China.
Cell death discovery
|May 13, 2024
概括
在结直肠癌 (CRC) 中,高HTRA1表达通过通过SLC7A11.11抑制铁亡来促进化学抵抗. 向HTRA1可能会逆转耐药性并改善患者的预后.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 化疗对于结肠直肠癌 (CRC) 是至关重要的,但由于耐化学反应,往往会失败.
- 脂质过氧化失衡介导的铁亡越来越多地与CRC中的化学抵抗有关.
- 向铁亡途径是克服瘤化学抵抗的潜在策略.
研究的目的:
- 调查HtrA血清蛋白酶1 (HTRA1) 在结直肠癌进展和化学抵抗中的作用.
- 阐明HTRA1影响化学抵抗的潜在机制,特别是与铁亡的联系.
主要方法:
- 查和识别HTRA1作为CRC进展和化学抵抗相关的基因.
- 功能增益和丧失分析,以评估HTRA1对CRC细胞增殖的影响.
- 丰富分析,电子显微镜,ROS和MDA水平测试,以探索HTRA1对铁亡的作用.
- 验证HTRA1与SLC7A11的相互作用及其对SLC7A11表达的影响.
主要成果:
- 在CRC细胞中HTRA1的表达很高,与预后不佳相关.
- HTRA1促进CRC细胞的增殖,并参与化疗抵抗.
- HTRA1显著影响铁,由细胞和生物化学分析证实.
- HTRA1与SLC7A11相互作用,上调其表达,从而抑制铁,导致CRC细胞中的5-FU/L-OHP耐药性.
结论:
- 在促进结直肠癌化学抵抗方面,HTRA1通过通过SLC7A11通路抑制铁亡起着至关重要的作用.
- 在CRC中,HTRA1代表了克服化学抵抗的潜在治疗标.
- 对于结直肠癌患者来说,HTRA1可能是有价值的预后指标.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
01:06Carrier-Mediated Transport
411
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
411
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:46Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K